Good morning, everyone, and welcome to the annual meeting of shareholders of Theratechnologies. Bonjour a tous et bienvenue a notre assemblee annuelle des actionnaires. My name is Dawn Svoronos, and I'm the Chair of the Board of Theratechnologies. I'll be presiding over the meeting today. The following persons of the corporation are also present at the meeting. Paul Lévesque, President and CEO of Theratechnologies. Philippe Dubuc, Senior Vice President and Chief Financial Officer. Jocelyn Lafond, General Counsel and Corporate Secretary. Also with me today are Christian Marsolais, Senior Vice President and Chief Medical Officer, and John Leasure, Global Commercial Officer. Je m'appelle Dawn Svoronos et je suis la Presidente du conseil de Theratechnologies. J'agirai comme Presidente de l'assemblee, et les personnes suivantes sont egalement presentes a l'assemblee. Paul Lévesque, President et Chef de la direction de la societe. Philippe Dubuc, Vice-President Senior et Chef des finances. Jocelyn Lafond, General Counsel and Corporate Secretary. Christian Marsolais, Senior Vice President and Chief Medical Officer. John Leasure, Global Commercial Officer. This meeting is being held virtually via a live audio-video webcast. Here are a few guidelines for the orderly conduct of the meeting. First, the meeting will be conducted in English, given that a large amount of U.S. shareholders have logged in to the meeting. During the question period, we will be answering questions in the language they are asked in. Second, voting on all matters by registered shareholders and duly appointed proxy holders will be conducted via electronic ballot. If you have already voted using the proxy form or a voting information form, then no further action is required on your part. Please note that if you choose to vote again, only your vote cast during the meeting will be counted, and the vote that you submitted by proxy will be revoked. The poll will be open for all motions and resolutions at the same time. This will allow you to choose to vote on each motion and resolution immediately or to wait until the conclusion of discussion prior to casting your vote. Once discussion on all items of business has concluded, we'll give you 1 minute to record your vote on the online platform in case you have not already done so, and then declare voting closed on all resolutions. Once the electronic balloting closes, your votes will be automatically submitted. Questions may be submitted at any time by registered shareholders, duly appointed proxy holders, or guests throughout the meeting using the instant messaging service of the virtual interface. Please note that there will be a slight delay in the publication of the communications received. We will try to answer as many questions as possible during the question period at the end of the meeting. Questions regarding procedural matters or directly related to a specific motion will be addressed during the meeting. Results of the votes on each business item will be compiled by the scrutineers at the end of the meeting and will be communicated by press release after the meeting. The final voting results will also be filed on the SEDAR and EDGAR websites. We will now proceed with the formal portion of today's meeting. To expedite this formal part of the meeting, I will move the motions, and Philippe Dubuc will second them. I confirm that we are both shareholders of the corporation. I now declare the polls open on all resolutions. I now ask that the annual general meeting of shareholders of the corporation comes to order. I appoint Jocelyn Lafond as Secretary of the meeting. For the purposes of this meeting, I appoint Computershare Trust Company of Canada through its representatives as scrutineers to compute the votes on any polls taken at this meeting and to report thereon to the Secretary of the meeting. The purposes of today's meeting are set out in the management proxy circular of the corporation dated April 6, 2023. I have been advised that the notice of meeting, the management proxy circular, and the form of proxy or voting instruction form, as applicable, were mailed to shareholders on or around April 12, 2023. That the audited consolidated financial statements of the corporation for the fiscal year ended November 30, 2022, and the related MD&A were mailed to shareholders of the corporation who requested such statements and the related MD&A on or around March 10, 2023. Copies of the management proxy circular and other meeting materials are also available under the corporation's website and under the corporation's profile on the SEDAR and EDGAR websites. Our transfer agent, Computershare Trust Company of Canada, has attested to the proper mailing of the notice of meeting, proof of meeting. Proof of service of such meeting has been provided to me by the corporation's transfer agent. I direct that a copy of such proof of service be annexed to the minutes of this meeting. I've been advised that persons representing more than 10% of the aggregate number of votes attached to all common shares for the meeting are present or duly represented by proxy at the meeting, and therefore, a quorum of shareholders of the corporation is present, and the meeting is properly called and duly constituted for the transaction of business. I have received the scrutineer's report, and I direct that their formal report be annexed to the minutes of this meeting. I have read the minutes of last year's annual meeting of shareholders, and I'm satisfied with their content. I propose a motion to exempt the secretary of the corporation from reading last year's minutes and to adopt said minutes. I second this motion. The first item of business on the agenda for today's meeting is the receipt of the audited consolidated financial statements of the corporation as at and for the fiscal year ended November 30th, 2022 and 2021, together with the auditor's report thereon. Copies of such documents have been mailed to the shareholders who requested such statements and are available on our website and under the corporation's profile on the SEDAR and EDGAR websites. I ask that the secretary of the meeting table those documents in the record of the meeting. The next item of business is the election of directors. The number of directors to be elected at the meeting is set at nine, and each director will hold office until the close of business of the next annual meeting of shareholders of the corporation following election or until his or her successor is elected or appointed. Each of the persons nominated has confirmed that he or she is prepared to serve as director. The nominees to act as directors of the corporation for the ensuing year are Joseph Arena, Frank Holler, Gérald Lacoste, Paul Lévesque, Gary Littlejohn, Andrew Molson, Alain Trudeau, Dale Weil, and myself, Dawn Svoronos. As explained in the management proxy circular, only the persons nominated in accordance with the corporation's advance notice of bylaw may be proposed for election at the meeting in this regard. I was informed before the meeting that no other nominations were received in accordance with the advance notice bylaw. To date, more than 50% of the common shares present or represented by proxy at the meeting have been voted for these nominees, and the percentage of vote received for each of them was collected by our transfer agent before the meeting. I propose a motion for the nomination of the following persons as directors of the corporation. beside each name, I will give you the percent vote. Joseph Arena, 73.12%. Frank Holler, 72.89%. Gérald Lacoste, 58.15%. Paul Lévesque, 72.93%. Gary Littlejohn, 58.68%. Andrew Molson, 72.20%. Dale Weil, 72.20%. Alain Trudeau, 69.35%. Myself, Dawn Svoronos, 71.81%. I second this motion. Thank you, Philippe. We'll move to the next item of business while votes are being cast. The next item of business is the appointment of the auditors of the corporation for the ensuing year and the authorization that compensation for their services be determined by the board of directors of the corporation. The corporation recommends that KPMG Chartered Professional Accountants be appointed as the auditors of the corporation for the current fiscal year. To date, more than 50% of the common shares present or represented by proxy at the meeting have been voted, and 91.90% of those votes received before the meeting were cast for the appointment of KPMG as auditors of the corporation and to authorize the directors to set their compensation. I propose a motion for the appointment of KPMG as auditors of the corporation and to authorize the directors to set their compensation. I second this motion. Thank you, Philippe. We'll move to the next item of business while votes are being cast. The final item of business is the passing of Resolution 2023-1, approving certain amendments to the Corporation's share option plan. The reasons leading up to these amendments are mentioned in the management proxy circular, and the full text of Resolution 2023-1 is attached to the management proxy circular. The Corporation recommends the passing of Resolution 2023-1. To date, more than 50% of the common shares present or represented by proxy at the meeting have been voted, and 63.57% of those votes received before the meeting were cast for the passing of Resolution 2023-1. I propose a motion for the passing of Resolution 2023-1 approving certain amendments to the Corporation's share option plan. I second this motion. Thank you, Philippe. We'll now wait a brief moment to allow registered shareholders and duly appointed proxy holders to submit their vote on business matters requiring their vote. I have been advised by the scrutineers that the ballots and proxies deposited for the meeting have been voted in favor of all the business matters identified in the notice of meeting. I thus declare the election of the directors of the corporation proposed in the management proxy circular for the ensuing year, the appointment of KPMG as the auditors of the corporation for the ensuing year, and the authorization of the directors of the corporation to set their compensation. Three, the passing of Resolution 2023-1, approving certain amendments to the corporation's share option plan. I direct that the results of the poll be included in the minutes of this meeting, and that the voting results be announced in a press release in accordance with the policies of the Toronto Stock Exchange and filed on the SEDAR and EDGAR websites. We'll now proceed with our review of the salient business activities that occurred during the 2022 fiscal year and provide you with our perspective on 2023. I'll start. Since we met about a year ago, the biotech and broader capital markets have continued their tumultuous course. While Theratechnologies' share price has not been spared the realities of the market at large, we remain differentiated as both a commercial enterprise and developer of a novel oncology program. There are a few key elements that I believe marked this year. When Paul joined the team a few years ago, we knew that he would put a fresh perspective to our business, which he put into play by hiring new leadership and bringing the sales team on board, reducing our reliance on external organizations to grow sales. As we see now, this has had a material positive impact on the top line. We have full confidence in the team towards our new profitability journey with revenue targets that are achievable. We also had to make the hard decision to leave Europe this past year. It was not easy, but it was the right decision to make at that time. Looking back, it is even more clear to us that the exit was necessary and a good business decision. With respect to our pipeline, drug development is never a straightforward path, and we came face to face with that reality last December. With the voluntary pause in the TH1902 program, we took decisive action and made an agile pivot. For these reasons, I'd like to tip my hat to the Theratechnologies team for both their resilience and hard work in a challenging environment. We believe that the modifications made to the commercial business and pipeline programs will keep us on track to building sustainable shareholder value and the long-term growth that we have spoken of so many times already. As we fast-forward to today, we have a strong commercial business that is delivering consistent long-term growth and an oncology program that is expected to return to the clinic stronger, more focused, and optimized for success. The management team has also been tasked with effectively controlling expenses on a path towards reaching positive adjusted EBITDA. Kudos to the team for getting through this period and working towards a new plan that we are confident will return shareholder value in a very tough environment. Finally, I would like to take this opportunity to thank all of our shareholders for their support throughout this journey. With that, I'd like to turn the call over to our CEO, Paul. Thank you, Dawn, for putting our company's long-term prospect into perspective. Good morning to everyone on the call today. I want to be brief, just to remind everyone of a few upcoming strategic catalysts and milestones. Just as Dawn has mentioned, I want to stress again all of the hard work that our team has put into the business this past year. While our stock price has not escaped the realities of a depressed biotech sector, we remain on solid ground because of our commercial line of business and our path towards achieving a positive adjusted EBITDA. With this in mind, we're also happy to report the filing of TH1902's amended protocol to the FDA. We continue to remain optimistic for our oncology program, which now follows the recommendations of a leading panel of independent oncology experts. In supporting TH1902 at this current stage of its development life cycle, we are prudently moving forward with oncology program that is not only worth investigating, but has a chance of greatly increasing the potential valuation of Theratechnologies. Once the FDA approves the amended protocol, we're looking forward to updating the market and plan to hold a conference call with analysts and investors in order to provide insights on the changes made to the protocol and the rationale for doing so. As previously announced, the three main areas of protocol improvements include addressing the dosage regimen, patient selection criteria, as well as tumor types. Additionally, once the trial resumes, we have made the decision to pursue partnership outside of our original scope of target territories, which we believe could greatly broaden the number of potential companies that we could partner with, especially with the new information presented at the ACR meeting. Not only do we believe that TH1902 can offer partnership opportunities as a single agent, but we now know of its synergistic effect with anti-PD-L1 therapies, further opening us up to new possibilities in therapies with unmet needs. As our commercial strategy was discussed during our last earnings call, we believe we are on the right path towards meeting our objectives of achieving a positive adjusted EBITDA. For the current fiscal year, achieving top line net revenue of between $90 million-$95 million, or sales growth of between 13% or 19%. We continue to have a strong handle on the commercial side of our business and anticipate strong growth through product innovation and increases in franchise scripts for years to come. As such, we remain convinced that this new way of operating will generate value for our shareholders. With this, I would like to turn to Philippe for the forward-looking statements. Thank you. Before we read and answer questions from shareholders, I'd like to remind everyone that the remarks made by Dawn Svoronos and Paul Lévesque contain forward-looking statements regarding Theratechnologies' future plans, expectations, and intentions with respect to future events. These forward-looking statements were based on certain assumptions, and there are risks that results obtained by Theratechnologies differ materially from those statements. As such, Theratechnologies cannot guarantee that any forward-looking statement will materialize, and you are cautioned not to place undue reliance on them. Forward-looking statements represent Theratechnologies expectations as of this morning, May 9, 2023. I refer current and potential investors to the forward-looking information and risk factor sections of our annual information form, dated February 27th, 2023, available on SEDAR at sedar.com and on EDGAR at sec.gov as an exhibit to our Form 40-F dated February 28th, 2023, for a description of our assumptions and risks. Additionally, today we have used the term adjusted EBITDA, which is not a financial measure under international financial reporting standards or U.S. GAAP principles. Adjusted EBITDA excludes the effects of certain items that primarily reflect the impact of long-term investment and financing decisions rather than the results of day-to-day operations. Dawn Svoronos? Thanks, Philippe. We'll now proceed with the question and answer period. I'd ask that all those who would like to ask a question use the instant messaging feature of the virtual interface to do so. A member of management or myself, as appropriate, will respond. We'll answer as many questions as time permits. Please limit your questions to topics relating to today's subject matter and keep your questions short and to the point. We will now give you a moment to type in your questions. For each question we answer, we'll summarize the question. We'd like to remind you that questions which were already answered or that are redundant or repetitive will not be published nor answered. There are no questions at time. Okay. There are no questions. This concludes today's agenda. Thank you for attending today, and thank you again for your support of Theratechnologies.